Skip to main
  1. Stocks
  2. LENZ Therapeutics Inc
  3. Forecast
LENZ

LENZ Stock Forecast & Price Target

LENZ Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 0%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

LENZ Therapeutics is benefiting from clear early commercial traction, with VIZZ sales rising 53% quarter over quarter to $2.6MM and paid prescriptions topping 38K, while more than 15K unique prescribers and 75% repeat writers suggest strong clinician acceptance. The investment case is further supported by VIZZ’s differentiated aceclidine mechanism, rapid onset, and all-day durability up to 10 hours, alongside refill and retention signals such as over 60% of e-pharmacy patients buying more than one monthly pack since launch. Management’s strategic reorganization, telehealth emphasis, and projected 2027 annualized operating expense reduction of greater than 50% improve operating leverage, even as consumer marketing remains the key growth engine.

Bears say

LENZ Therapeutics is facing a weaker-than-expected commercial launch, with 3Q26 revenues of $3.4M versus $4.2M consensus and $6.0M estimated, while SG&A rose to $35.8M and the company posted a $31.0M net loss, or $0.99 per diluted share. The balance sheet shows $197.3M in cash and equivalents as of September 30, 2026, but that cushion is being consumed by ongoing operating losses and uncertain near-term monetization. Investor sentiment is further pressured by a December 2025 FAERS retinal tear report for VIZZ, which amplifies clinical, regulatory, and commercialization risk while management is still dependent on awareness and Rx growth to restore confidence.

LENZ has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 0% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LENZ Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

LENZ Analyst Forecast & Price Prediction

Get the latest LENZ stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in LENZ

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LENZ Therapeutics Inc (LENZ) Forecast

Analysts have given LENZ a Strong Buy based on their latest research and market trends.

According to 5 analysts, LENZ has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LENZ Therapeutics Inc (LENZ)


LENZ Analyst Forecast & Price Prediction

Get the latest LENZ stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in LENZ

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover LENZ stock data and trends